|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1550 AUD | 0.00% |
|
-3.12% | -8.82% |
| 10/07 | Neurizon Therapeutics Receives US FDA Support to Lift Clinical Hold on ALS Trial | MT |
| 03/07 | Elanco Animal Health Enters Into Licensing Agreement With Neurizon for Monepantel | MT |
Company Valuation: Neurizon Therapeutics Limited
Data adjusted to current consolidation scope
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 10.65 | 46.81 | 28.82 | 22.18 | 26.06 | 86.78 |
| Change | - | 339.63% | -38.43% | -23.03% | 17.48% | 232.99% |
| Enterprise Value (EV) 1 | 8.878 | 45.4 | 27.08 | 21.15 | 24.39 | 76.05 |
| Change | - | 411.37% | -40.36% | -21.89% | 15.31% | 211.83% |
| P/E ratio | -5.37x | -33.7x | -21.5x | -13x | -3.88x | -9.42x |
| PBR | 1.43x | 5.49x | 3.25x | 2.83x | 6.7x | 8.48x |
| PEG | - | 1x | 2.71x | -0.5x | -0x | -1.36x |
| Capitalization / Revenue | 2.45x | 11.4x | 7.88x | 4.92x | 6.82x | 103x |
| EV / Revenue | 2.04x | 11x | 7.4x | 4.69x | 6.39x | 90.4x |
| EV / EBITDA | -6.58x | -41.5x | -24.4x | -14.6x | -7.91x | -13.1x |
| EV / EBIT | -5.84x | -36.4x | -21.3x | -13.1x | -7.5x | -13.1x |
| EV / FCF | -7.77x | -50.7x | -44x | -27.5x | -58x | -20.8x |
| FCF Yield | -12.9% | -1.97% | -2.27% | -3.63% | -1.72% | -4.8% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.007072 | -0.0046 | -0.004235 | -0.00539 | -0.0194 | -0.0207 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 4.347 | 4.12 | 3.657 | 4.51 | 3.819 | 0.8417 |
| EBITDA 1 | -1.349 | -1.094 | -1.109 | -1.453 | -3.081 | -5.815 |
| EBIT 1 | -1.521 | -1.247 | -1.273 | -1.62 | -3.254 | -5.817 |
| Net income 1 | -1.551 | -1.362 | -1.337 | -1.708 | -6.212 | -7.673 |
| Net Debt 1 | -1.77 | -1.413 | -1.746 | -1.035 | -1.673 | -10.73 |
| Reference price 2 | 0.0380 | 0.1550 | 0.0910 | 0.0700 | 0.0750 | 0.1950 |
| Nbr of stocks (in thousands) | 2,80,221 | 3,02,021 | 3,16,730 | 3,16,912 | 3,47,475 | 4,45,024 |
| Announcement Date | 19/09/19 | 18/09/20 | 18/08/21 | 26/08/22 | 31/08/23 | 30/08/24 |
1AUD in Million2AUD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 4.99Cr | ||
| 37.15x | 12.26x | 27.92x | 0.75% | 71TCr | ||
| 14.75x | 4.45x | 12.66x | 3.18% | 40TCr | ||
| 26.07x | 6.52x | 13.7x | 3.43% | 34TCr | ||
| 16.67x | 6.04x | 12.08x | 3.04% | 30TCr | ||
| 14.12x | 3.48x | 8.61x | 3.85% | 26TCr | ||
| 17.19x | 4.58x | 11.09x | 3.32% | 23TCr | ||
| 22.1x | 4.13x | 12.15x | 2.29% | 22TCr | ||
| 10.56x | 3.43x | 7.41x | 3.9% | 21TCr | ||
| 22.86x | 5.83x | 11.25x | 3.21% | 16TCr | ||
| Average | 20.16x | 5.64x | 12.99x | 3% | 28.21TCr | |
| Weighted average by Cap. | 22.80x | 6.73x | 15.55x | 2.64% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- NUZ Stock
- Valuation Neurizon Therapeutics Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition